Jump to content

Victor Kande

Daga Wikipedia, Insakulofidiya ta kyauta.
Victor Kande
Rayuwa
Karatu
Makaranta Université de Kinshasa (en) Fassara
Sana'a
Sana'a scientist (en) Fassara
Employers Université de Kinshasa (en) Fassara
ministry of health (en) Fassara
Muhimman ayyuka African trypanosomiasis (en) Fassara
Kyaututtuka

 

Victor Kande Betu Kumeso likita ne ɗan ƙasar Kongo wanda kwararre ne a kan trypanosomiasis na Afirka. Yana aiki a Shirin National de Lutte contre la Trypanosomiase Humaine Africaine a Jami'ar Kinshasa.

Rayuwar farko da ilimi

[gyara sashe | gyara masomin]

Kande ya yi karatun likitanci. Yana da shekaru 27, shi kaɗai ne likita ga mutane 11,000 a lardin Bandundu.[1]

Bincike

[gyara sashe | gyara masomin]

An san Kande a matsayin uban ciwon barci (Father of sleeping sickness). An naɗa shi Daraktan shirin cutar bacci na Jamhuriyar Demokradiyyar Kongo kuma yana aiki tare da Ma'aikatar Lafiya ta Jama'a.[1][2] trypanosomiasis na Afirka yana shafar mutane da yawa a Jamhuriyar Demokradiyyar Kongo.[3] Trypanosoma brucei ne ke haifar da cutar kuma yawanci yana nunawa a cikin nau'i na yau da kullun.[4] Yana binciken cututtukan cututtukan barci.[5] Ya kasance daya daga cikin na farko da ya ba da rahoton sake bullar cutar barci, inda ya yi kira da a kara ba da taimako, haɗin gwiwa tsakanin ƙasashe da ingantattun wuraren kiwon lafiya da zaɓin magani.[6]

Kande ya kasance babban mai bincike na bincike da yawa na sabbin jiyya na trypanosomiasis na Afirka.[7] Ya binciki inganci da amincin DB289, wanda ake gudanarwa a matsayin ƙwaƙƙwaran magani ga Pentamidine. Ya kuma nuna babban rashin nasara tare da Melarsoprol kuma ya bincika amfani da Pafuramidine.[8] A cikin ƙasar da ke da ƙananan hanyoyi ko asibitoci, Kande da abokan aikinsa sun ɗauki mutane 400 da ke da matuƙar mataki na Trypanosoma brucei don gwajin Fexinidazole wanda shirin Drugs for Neglected Diseases initiative.[9][10] The study demonstrated that fexinidazole is an effective treatment for sleeping sickness.[11][12] Binciken ya nuna cewa fexinidazole magani ne mai mahimmanci ga ciwon barci.[10][11][12] An buga aikin a cikin The Lancet kuma ya jagoranci Kande da Richard Lehman (likitan kulawa na farko) ya bayyana shi 'jarumin likita na gaskiya'. Fexinidazole ya sami kyakkyawan ra'ayi daga Hukumar Kula da Magunguna ta Turai a ƙarƙashin Mataki na 58 a cikin watan Nuwamba 2018[13] kuma an yi rajista a cikin Jamhuriyar Demokradiyyar Kongo a cikin watan Disamba 2018.[14]

Kande a halin yanzu tana binciken SCYX-7158 (acoziborole) a matsayin magani guda ɗaya don ɗan adam na Trypanosomiasis (HAT) a cikin gwajin asibiti wanda shirin Drugs for Neglected Diseases initiative.[15][16]

Yana neman sabbin hanyoyin haɗin gwiwa tsakanin kamfanoni masu zaman kansu da na jama'a, kamar haɗin gwiwar da ya haifar da isar da fexinidazole ta DNDi.[17] A cikin shekarar 2018 Kande an ba shi lambar yabo ta Anne Maurer Cecchini na Taron Lafiya na Geneva.[12]

Manazarta

[gyara sashe | gyara masomin]
  1. ↑ 1.0 1.1 Boseley, Sarah; Levene, David (2018-11-16). "The big sleep: how the world's most troubled country is beating a deadly disease". The Guardian (in Turanci). ISSN 0261-3077. Retrieved 2018-11-19.
  2. ↑ Trypanosomiasis, WHO Expert Committee on the Control and Surveillance of Human African; Organization, World Health (2013). Control and Surveillance of Human African Trypanosomiasis: Report of a WHO Expert Committee (in Turanci). World Health Organization. ISBN 9789241209847.
  3. ↑ "Human African trypanosomiasis in the Democratic Republic of the Congo: disease distribution and risk - Dimensions" (in Turanci). Retrieved 2018-11-20.
  4. ↑ Courtin, David; Jamonneau, Vincent; Mathieu, Jean-Francois; Koffi, Mathurin; Milet, Jacqueline; Yeminanga, Claude Sese; Kumeso, Victor Kande Betu; Cuny, Gerard; Bilengue, Constantin Miaka Mia (May 2006). "Comparison of cytokine plasma levels in human African trypanosomiasis". Tropical Medicine and International Health (in Turanci). 11 (5): 647–653. doi:10.1111/j.1365-3156.2006.01612.x. ISSN 1360-2276. PMID 16640617.
  5. ↑ Simo, Gustave; Diabakana, Philemon; Betu Ku Mesu, Victor; Manzambi, Emile; Ollivier, Gaelle; Asonganyi, Tazoacha; Cuny, Gerard; Grebaut, Pascal (2006). "Human African Trypanosomiasis Transmission, Kinshasa, Democratic Republic of Congo". Emerging Infectious Diseases (in Turanci). 12 (12): 1968–1970. doi:10.3201/eid1212.060516. ISSN 1080-6040. PMC 3291358. PMID 17326955.
  6. ↑ Van Nieuwenhove, Simon; Betu-Ku-Mesu, Victor Kande; Diabakana, Philemon Mansinsa; Declercq, Johan; Bilenge, Constantin Miaka Mia (May 2001). "Sleeping sickness resurgence in the DRC: the past decade". Tropical Medicine and International Health (in Turanci). 6 (5): 335–341. doi:10.1046/j.1365-3156.2001.00731.x. ISSN 1360-2276. PMID 11348528.
  7. ↑ "Trial of DB289 for the Treatment of Stage I African Trypanosomiasis - Full Text View - ClinicalTrials.gov" (in Turanci). Retrieved 2018-11-19.
  8. ↑ Burri, Christian; Yeramian, Patrick D.; Allen, James L.; Merolle, Ada; Serge, Kazadi Kyanza; Mpanya, Alain; Lutumba, Pascal; Mesu, Victor Kande Betu Ku; Bilenge, Constantin Miaka Mia (2016-02-16). "Efficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studies". PLOS Neglected Tropical Diseases (in Turanci). 10 (2): e0004362. doi:10.1371/journal.pntd.0004362. ISSN 1935-2735. PMC 4755713. PMID 26881924.
  9. ↑ "Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2 - Full Text View - ClinicalTrials.gov". clinicaltrials.gov (in Turanci). 17 February 2018. Retrieved 2019-07-29.
  10. ↑ 10.0 10.1 "Richard Lehman's journal review—13 November 2017 - The BMJ". The BMJ (in Turanci). 2017-11-13. Retrieved 2018-11-20.
  11. ↑ 11.0 11.1 Mesu, Victor Kande Betu Ku; Kalonji, Wilfried Mutombo; Bardonneau, Clélia; Mordt, Olaf Valverde; Blesson, Séverine; Simon, François; Delhomme, Sophie; Bernhard, Sonja; Kuziena, Willy (January 2018). "Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial". The Lancet (in English). 391 (10116): 144–154. doi:10.1016/S0140-6736(17)32758-7. ISSN 0140-6736. PMID 29113731. S2CID 46781585.CS1 maint: unrecognized language (link)
  12. ↑ 12.0 12.1 12.2 "Award Anne Maurer Cecchini | Geneva Health Forum 2018". Geneva Health Forum 2018 (in Turanci). Archived from the original on 2018-11-21. Retrieved 2018-11-19.
  13. ↑ CZARSKA-THORLEY, Dagmara (2018-11-16). "CHMP recommends first oral-only treatment for sleeping sickness". European Medicines Agency (in Turanci). Retrieved 2019-07-29.
  14. ↑ "Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo | DNDi". Drugs for Neglected Diseases initiative (DNDi) (in Turanci). 29 January 2019. Retrieved 2019-07-29.
  15. ↑ "ASTMH 2018 – DNDi". www.dndi.org (in Turanci). Retrieved 2018-11-19.
  16. ↑ "Prospective Study on Efficacy and Safety of SCYX-7158 in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense - Full Text View - ClinicalTrials.gov". clinicaltrials.gov (in Turanci). Retrieved 2019-07-29.
  17. ↑ "ASTMH 2018 – DNDi". www.dndi.org (in Turanci). Retrieved 2018-11-19.
Daga "https://ha.wikipedia.org/w/index.php?title=Victor_Kande&oldid=354931"